XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheet Components
 9 Months Ended
Sep. 30, 2018
Balance Sheet Components  
Balance Sheet Components

Note 5. Balance Sheet Components

Cash Equivalents and Available-for-sale Securities

Cash equivalents and available-for-sale securities consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2018

 

 

Amortized

 

Gross Unrealized

 

 

 

    

Cost

    

Gains

    

Losses

    

Fair Value

Money market funds

 

$

27,582

 

$

 —

  

$

—

 

$

27,582

Corporate bonds

 

 

6,031

 

 

 —

  

 

(11)

 

 

6,020

Commercial paper

 

 

62,386

 

 

 —

  

 

 —

 

 

62,386

Government bonds

 

 

39,261

 

 

 —

  

 

(69)

 

 

39,192

Total cash equivalents and available-for-sale securities

 

$
135,260

 

$

 —

  

$

(80)

 

$
135,180

Classified as:

 

 

 

  

 

 

  

 

 

  

 

 

Cash equivalents

 

 

 

  

 

 

  

 

 

  

$

84,090

Available-for-sale securities - current

 

 

 

  

 

 

  

 

 

  

 

51,090

Total cash equivalents and available-for-sale securities

 

 

 

  

 

 

  

 

 

  

$
135,180

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2017

 

 

Amortized

 

Gross Unrealized

 

 

 

    

Cost

    

Gains

    

Losses

    

Fair Value

Money market funds

 

$

48,704

 

$

 —

  

$

—

 

$

48,704

Corporate bonds

 

 

6,254

 

 

 —

  

 

(7)

 

 

6,247

Commercial paper

 

 

58,524

 

 

 —

  

 

—

 

 

58,524

Government bonds

 

 

40,428

 

 

 —

  

 

(125)

 

 

40,303

Total cash equivalents and available-for-sale securities

 

$

153,910

 

$

 —

  

$

(132)

 

$

153,778

Classified as:

 

 

 

  

 

 

  

 

 

  

 

 

Cash equivalents

 

 

 

  

 

 

  

 

 

  

$

104,348

Available-for-sale securities - current

 

 

 

  

 

 

  

 

 

  

 

37,972

  Available-for-sale securities - noncurrent

 

 

 

  

 

 

  

 

 

  

 

11,458

Total cash equivalents and available-for-sale securities

 

 

 

  

 

 

  

 

 

  

$

153,778

 

All available-for-sale securities - current held as of September 30, 2018 and December 31, 2017 had contractual maturities of less than one year. All available-for-sale securities - noncurrent held as of December 31, 2017 had contractual maturities of at least one year but less than two years. There were no material realized gains or realized losses on available-for-sale securities for the periods presented.

Accrued Expenses and Other Payables

Accrued expenses and other payables consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 

 

December 31, 

 

    

2018

    

2017

Accrued clinical and research related expenses

 

$

7,649

 

$

6,437

Accrued employee related expenses

 

 

2,410

 

 

2,718

Accrued professional service fees

 

 

332

 

 

267

Other

 

 

105

 

 

124

Total accrued expenses and other payables

 

$

10,496

 

$

9,546